Tags

Type your tag names separated by a space and hit enter

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
PLoS Negl Trop Dis. 2016 09; 10(9):e0004880.PN

Abstract

BACKGROUND

SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBisome and miltefosine are safe and effective in India, but there are no published data from trials of combination therapies including these drugs from Africa.

METHODS

A phase II open-label, non-comparative randomized trial was conducted in Sudan and Kenya to evaluate the efficacy and safety of three treatment regimens: 10 mg/kg single dose AmBisome plus 10 days of SSG (20 mg/kg/day), 10 mg/kg single dose AmBisome plus 10 days of miltefosine (2.5mg/kg/day) and miltefosine alone (2.5 mg/kg/day for 28 days). The primary endpoint was initial parasitological cure at Day 28, and secondary endpoints included definitive cure at Day 210, and pharmacokinetic (miltefosine) and pharmacodynamic assessments.

RESULTS

In sequential analyses with 49-51 patients per arm, initial cure was 85% (95% CI: 73-92) in all arms. At D210, definitive cure was 87% (95% CI: 77-97) for AmBisome + SSG, 77% (95% CI 64-90) for AmBisome + miltefosine and 72% (95% CI 60-85) for miltefosine alone, with lower efficacy in younger patients, who weigh less. Miltefosine pharmacokinetic data indicated under-exposure in children compared to adults.

CONCLUSION

No major safety concerns were identified, but point estimates of definitive cure were less than 90% for each regimen so none will be evaluated in Phase III trials in their current form. Allometric dosing of miltefosine in children needs to be evaluated.

TRIAL REGISTRATION

The study was registered with ClinicalTrials.gov, number NCT01067443.

Authors+Show Affiliations

Drugs for Neglected Diseases initiative, Nairobi, Kenya. Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.Drugs for Neglected Diseases initiative, Geneva, Switzerland.MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, United Kingdom.Drugs for Neglected Diseases initiative, Nairobi, Kenya.MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, United Kingdom.Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands. Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.KIT Biomedical Research, Amsterdam, the Netherlands.College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.Department of Medical Microbiology, Leishmaniasis Unit, College of Health Sciences, Makerere University, Kampala, Uganda.Drugs for Neglected Diseases initiative, Geneva, Switzerland.Drugs for Neglected Diseases initiative, Nairobi, Kenya. Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.Drugs for Neglected Diseases initiative, Geneva, Switzerland.Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.Drugs for Neglected Diseases initiative, Geneva, Switzerland.Drugs for Neglected Diseases initiative, Geneva, Switzerland.Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.

Pub Type(s)

Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27627654

Citation

Wasunna, Monique, et al. "Efficacy and Safety of AmBisome in Combination With Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial." PLoS Neglected Tropical Diseases, vol. 10, no. 9, 2016, pp. e0004880.
Wasunna M, Njenga S, Balasegaram M, et al. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. PLoS Negl Trop Dis. 2016;10(9):e0004880.
Wasunna, M., Njenga, S., Balasegaram, M., Alexander, N., Omollo, R., Edwards, T., Dorlo, T. P., Musa, B., Ali, M. H., Elamin, M. Y., Kirigi, G., Juma, R., Kip, A. E., Schoone, G. J., Hailu, A., Olobo, J., Ellis, S., Kimutai, R., Wells, S., ... Musa, A. (2016). Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. PLoS Neglected Tropical Diseases, 10(9), e0004880. https://doi.org/10.1371/journal.pntd.0004880
Wasunna M, et al. Efficacy and Safety of AmBisome in Combination With Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. PLoS Negl Trop Dis. 2016;10(9):e0004880. PubMed PMID: 27627654.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. AU - Wasunna,Monique, AU - Njenga,Simon, AU - Balasegaram,Manica, AU - Alexander,Neal, AU - Omollo,Raymond, AU - Edwards,Tansy, AU - Dorlo,Thomas P C, AU - Musa,Brima, AU - Ali,Mohammed Hassan Sharaf, AU - Elamin,Mohammed Yasein, AU - Kirigi,George, AU - Juma,Rashid, AU - Kip,Anke E, AU - Schoone,Gerard J, AU - Hailu,Asrat, AU - Olobo,Joseph, AU - Ellis,Sally, AU - Kimutai,Robert, AU - Wells,Susan, AU - Khalil,Eltahir Awad Gasim, AU - Strub Wourgaft,Nathalie, AU - Alves,Fabiana, AU - Musa,Ahmed, Y1 - 2016/09/14/ PY - 2016/02/22/received PY - 2016/07/06/accepted PY - 2016/9/15/entrez PY - 2016/9/15/pubmed PY - 2017/6/18/medline SP - e0004880 EP - e0004880 JF - PLoS neglected tropical diseases JO - PLoS Negl Trop Dis VL - 10 IS - 9 N2 - BACKGROUND: SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBisome and miltefosine are safe and effective in India, but there are no published data from trials of combination therapies including these drugs from Africa. METHODS: A phase II open-label, non-comparative randomized trial was conducted in Sudan and Kenya to evaluate the efficacy and safety of three treatment regimens: 10 mg/kg single dose AmBisome plus 10 days of SSG (20 mg/kg/day), 10 mg/kg single dose AmBisome plus 10 days of miltefosine (2.5mg/kg/day) and miltefosine alone (2.5 mg/kg/day for 28 days). The primary endpoint was initial parasitological cure at Day 28, and secondary endpoints included definitive cure at Day 210, and pharmacokinetic (miltefosine) and pharmacodynamic assessments. RESULTS: In sequential analyses with 49-51 patients per arm, initial cure was 85% (95% CI: 73-92) in all arms. At D210, definitive cure was 87% (95% CI: 77-97) for AmBisome + SSG, 77% (95% CI 64-90) for AmBisome + miltefosine and 72% (95% CI 60-85) for miltefosine alone, with lower efficacy in younger patients, who weigh less. Miltefosine pharmacokinetic data indicated under-exposure in children compared to adults. CONCLUSION: No major safety concerns were identified, but point estimates of definitive cure were less than 90% for each regimen so none will be evaluated in Phase III trials in their current form. Allometric dosing of miltefosine in children needs to be evaluated. TRIAL REGISTRATION: The study was registered with ClinicalTrials.gov, number NCT01067443. SN - 1935-2735 UR - https://www.unboundmedicine.com/medline/citation/27627654/Efficacy_and_Safety_of_AmBisome_in_Combination_with_Sodium_Stibogluconate_or_Miltefosine_and_Miltefosine_Monotherapy_for_African_Visceral_Leishmaniasis:_Phase_II_Randomized_Trial_ L2 - https://dx.plos.org/10.1371/journal.pntd.0004880 DB - PRIME DP - Unbound Medicine ER -